Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 11 (November)

1. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis.
   Int J Cancer, 118(1): 62-73. [Abstract] [Full-text]
2. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.
   Int J Cancer, 118(1): 222-9. [Abstract] [Full-text]
3. Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells.
   Cancer Res, 65(21): 9934-42. [Abstract] [Full-text]
4. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer.
   Cancer Res, 65(21): 9906-13. [Abstract] [Full-text]
5. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation.
   Cancer Res, 65(21): 9891-8. [Abstract] [Full-text]
6. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.
   Cancer Res, 65(21): 9807-16. [Abstract] [Full-text]
7. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis.
   Cancer Res, 65(21): 9789-98. [Abstract] [Full-text]
8. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness.
   Cancer Res, 65(21): 9762-70. [Abstract] [Full-text]
9. Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase.
   Cancer Res, 65(21): 9617-22. [Abstract] [Full-text]
10. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Cancer Res, 65(21): 9611-6. [Abstract] [Full-text]
11. Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells.
    Oncogene, 24(48): 7203-12. [Abstract] [Full-text]
12. Molecular characterisation of the t(1;15)(p22;q22) translocation in the prostate cancer cell line LNCaP.
    Cytogenet Genome Res, 112(1): 45-52. [Abstract] [Full-text]
13. Hyperthermia combined with radiation in treatment of locally advanced prostate cancer is associated with a favourable toxicity profile.
    Int J Hyperthermia, 21(7): 649-56. [Abstract] [Full-text]
14. Life-threatening meningitis resulting from transrectal prostate biopsy.
    Asian J Androl, 7(4): 453-5. [Abstract] [Full-text]
15. Contragestazol (DL111-IT) inhibits proliferation of human androgen-independent prostate cancer cell line PC3 in vitro and in vivo.
    Asian J Androl, 7(4): 389-93. [Abstract] [Full-text]
16. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
    Asian J Androl, 7(4): 375-80. [Abstract] [Full-text]
17. Recent neuroanatomical studies on the neurovascular bundle of the prostate and cavernosal nerves: clinical reflections on radical prostatectomy.
    Asian J Androl, 7(4): 339-49. [Abstract] [Full-text]
18. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
    Urology, 66(5): 1060-5. [Abstract] [Full-text]
19. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Urology, 66(5): 1054-9. [Abstract] [Full-text]
20. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy.
    Urology, 66(5): 1048-53. [Abstract] [Full-text]
21. Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies.
    Urology, 66(5): 1043-7. [Abstract] [Full-text]
22. Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages.
    Urology, 66(5): 1038-42. [Abstract] [Full-text]
23. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
    Urology, 66(5): 1029-33. [Abstract] [Full-text]
24. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer.
    Urology, 66(5): 1024-8. [Abstract] [Full-text]
25. Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer.
    Urology, 66(5): 1020-3. [Abstract] [Full-text]
26. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients.
    Urology, 66(5): 1015-9. [Abstract] [Full-text]
27. Chromogranin A expression in familial versus sporadic prostate cancer.
    Urology, 66(5): 1010-4. [Abstract] [Full-text]
28. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome.
    Urology, 66(5): 930-4. [Abstract] [Full-text]
29. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers.
    Tumour Biol, 26(6): 324-36. [Abstract] [Full-text]
30. Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients.
    Int J Cancer, 118(2): 518-20. [Abstract] [Full-text]
31. Akt-regulated pathways in prostate cancer.
    Oncogene, 24(50): 7465-74. [Abstract] [Full-text]
32. Development and evaluation of a prostate sexual rehabilitation clinic: a pilot project.
    BJU Int, 96(9): 1360-4. [Abstract] [Full-text]
33. Perianal and intrarectal anaesthesia for transrectal biopsy of the prostate: a prospective randomized study comparing lidocaine-prilocaine cream and placebo.
    BJU Int, 96(9): 1264-7. [Abstract] [Full-text]
34. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy.
    BJU Int, 96(9): 1258-63. [Abstract] [Full-text]
35. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
    BJU Int, 96(9): 1253-7. [Abstract] [Full-text]
36. Factors contributing to the racial differences in prostate cancer mortality.
    BJU Int, 96(9): 1247-52. [Abstract] [Full-text]
37. A tumour stem cell hypothesis for the origins of prostate cancer.
    BJU Int, 96(9): 1219-23. [Abstract] [Full-text]
38. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse.
    Endocrinology, 146(12): 5188-96. [Abstract] [Full-text]
39. Evaluation of lipophilins as determinants of tumor cell response to estramustine.
    J Pharmacol Exp Ther, 315(3): 1158-62. [Abstract] [Full-text]
40. Contact stimulation of prostate cancer cell migration: the role of gap junctional coupling and migration stimulated by heterotypic cell-to-cell contacts in determination of the metastatic phenotype of Dunning rat prostate cancer cells.
    Biol Cell, 97(12): 893-903. [Abstract] [Full-text]
41. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Int J Radiat Oncol Biol Phys, 63(5): 1463-8. [Abstract] [Full-text]
42. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
    Int J Radiat Oncol Biol Phys, 63(5): 1455-62. [Abstract] [Full-text]
43. Effect of post-implant edema on prostate brachytherapy treatment margins.
    Int J Radiat Oncol Biol Phys, 63(5): 1469-73. [Abstract] [Full-text]
44. A phase III randomized, placebo-controlled, double-blind study of misoprostol rectal suppositories to prevent acute radiation proctitis in patients with prostate cancer.
    Int J Radiat Oncol Biol Phys, 63(5): 1488-93. [Abstract] [Full-text]
45. Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients.
    Int J Radiat Oncol Biol Phys, 63(5): 1483-7. [Abstract] [Full-text]
46. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
    Int J Radiat Oncol Biol Phys, 63(5): 1474-82. [Abstract] [Full-text]
47. An evaluation of general and spinal anesthesia techniques for prostate brachytherapy in a day surgery setting.
    Anesth Analg, 101(6): 1656-8. [Abstract] [Full-text]
48. Prostate epithelial stem cells.
    Cell Prolif, 38(6): 363-74. [Abstract] [Full-text]
49. Antibody levels against BK virus and prostate, kidney and bladder cancers in the EPIC-Oxford cohort.
    Br J Cancer, 93(11): 1305-6. [Abstract] [Full-text]
50. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse.
    Br J Cancer, 93(11): 1285-94. [Abstract] [Full-text]
51. Prostate cancer: three-dimensional sonoelastography for in vitro detection.
    Radiology, 237(3): 981-5. [Abstract] [Full-text]
52. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
    Cancer Chemother Pharmacol, 57(1): 46-51. [Abstract] [Full-text]
53. Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.
    J Surg Oncol, 92(4): 326-30. [Abstract] [Full-text]
54. E2F1 expression in LNCaP prostate cancer cells deregulates androgen dependent growth, suppresses differentiation, and enhances apoptosis.
    Prostate, 66(1): 70-81. [Abstract] [Full-text]
55. Effect of increasing ratio of estrogen: androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP.
    Prostate, 66(1): 105-14. [Abstract] [Full-text]
56. Differential attenuation of oxidative/nitrosative injuries in early prostatic neoplastic lesions in TRAMP mice by dietary antioxidants.
    Prostate, 66(1): 57-69. [Abstract] [Full-text]
57. Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation.
    Prostate, 66(1): 82-7. [Abstract] [Full-text]
58. Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer.
    Prostate, 66(1): 97-104. [Abstract] [Full-text]
59. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue.
    Prostate, 66(1): 13-8. [Abstract] [Full-text]
60. Changes in gap junctional connexin isoforms during prostate cancer progression.
    Prostate, 66(1): 19-31. [Abstract] [Full-text]
61. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
    Prostate, 66(1): 32-48. [Abstract] [Full-text]
62. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma.
    Prostate, 66(1): 49-56. [Abstract] [Full-text]
63. Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival.
    Biochem Biophys Res Commun, 339(1): 93-8. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.